Literature DB >> 30030271

Incident Atrial Fibrillation and the Risk of Stroke in Adults with Chronic Kidney Disease: The Stockholm CREAtinine Measurements (SCREAM) Project.

Juan Jesus Carrero1, Marco Trevisan1, Manish M Sood2, Peter Bárány3, Hong Xu1, Marie Evans3, Leif Friberg4, Karolina Szummer5.   

Abstract

BACKGROUND AND OBJECTIVES: Patients with CKD have a high risk of atrial fibrillation. Both CKD and atrial fibrillation are associated with higher risk of stroke and death. However, the effect of incident atrial fibrillation on stroke risk among patients with CKD is unknown. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Our study included adults with CKD (eGFR<60 ml/min per 1.73 m2) without previously documented atrial fibrillation who had been in contact with health care in Stockholm, Sweden during 2006-2011. Incident atrial fibrillation was identified by administrative diagnostic codes in outpatient or inpatient care and treated as a time-updated exposure in the analysis of stroke and death risk. Stroke events and deaths were ascertained from regional and national registers with complete coverage. Covariates included demographics, comorbidities, therapeutic procedures, and medications. Multivariable Cox regression analysis and competing risk analysis (accounting for death) were used to estimate the association between incident atrial fibrillation and stroke.
RESULTS: Among 116,184 adults with CKD, 13,412 (12%) developed clinically recognized atrial fibrillation during a mean follow-up of 3.9 years (interquartile range, 2.3-5.7 years). Incidence of atrial fibrillation increased across lower eGFR strata: from 29.4 to 46.3 atrial fibrillations per 1000 person-years in subjects with eGFR=45-60 and <30 ml/min per 1.73 m2, respectively; 1388 (53.8 per 1000 person-years) cases of stroke and 5592 (205.1 per 1000 person-years) deaths occurred after incident atrial fibrillation compared with 6850 (16.6 per 1000 person-years) cases of stroke and 28,613 (67.5 per 1000 person-years) deaths during periods without atrial fibrillation. After adjustment, incident atrial fibrillation was associated with higher risk of stroke (hazard ratio, 2.00; 95% confidence interval, 1.88 to 2.14) and death (hazard ratio, 1.76; 95% confidence interval, 1.71 to 1.82). This was attributed to both ischemic stroke (hazard ratio, 2.11; 95% confidence interval, 1.96 to 2.28) and intracranial bleeds (hazard ratio, 1.64; 95% confidence interval, 1.42 to 1.90). Stroke risk was similar across all eGFR strata. In competing risk analyses accounting for death, the association between incident atrial fibrillation and stroke was attenuated but remained higher (subhazard ratio, 1.49; 95% confidence interval, 1.39 to 1.60).
CONCLUSIONS: Patients with CKD who develop atrial fibrillation are at higher risk of stroke and death.
Copyright © 2018 by the American Society of Nephrology.

Entities:  

Keywords:  Atrial Fibrillation; Brain Ischemia; Follow-Up Studies; Incidence; Intracranial Hemorrhages; Patient Care; Renal Insufficiency, Chronic; Risk; Stroke; cardiovascular disease; chronic kidney disease; glomerular filtration rate

Year:  2018        PMID: 30030271      PMCID: PMC6140568          DOI: 10.2215/CJN.04060318

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN: 1555-9041            Impact factor:   8.237


  35 in total

1.  Impact of Renal Function on Outcomes With Edoxaban in the ENGAGE AF-TIMI 48 Trial.

Authors:  Erin A Bohula; Robert P Giugliano; Christian T Ruff; Julia F Kuder; Sabina A Murphy; Elliott M Antman; Eugene Braunwald
Journal:  Circulation       Date:  2016-07-05       Impact factor: 29.690

Review 2.  2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society.

Authors:  Craig T January; L Samuel Wann; Joseph S Alpert; Hugh Calkins; Joaquin E Cigarroa; Joseph C Cleveland; Jamie B Conti; Patrick T Ellinor; Michael D Ezekowitz; Michael E Field; Katherine T Murray; Ralph L Sacco; William G Stevenson; Patrick J Tchou; Cynthia M Tracy; Clyde W Yancy
Journal:  J Am Coll Cardiol       Date:  2014-03-28       Impact factor: 24.094

3.  Incident atrial fibrillation and risk of end-stage renal disease in adults with chronic kidney disease.

Authors:  Nisha Bansal; Dongjie Fan; Chi-yuan Hsu; Juan D Ordonez; Greg M Marcus; Alan S Go
Journal:  Circulation       Date:  2012-12-28       Impact factor: 29.690

4.  The contribution of chronic kidney disease to the global burden of major noncommunicable diseases.

Authors:  William G Couser; Giuseppe Remuzzi; Shanthi Mendis; Marcello Tonelli
Journal:  Kidney Int       Date:  2011-10-12       Impact factor: 10.612

5.  Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: the Framingham study.

Authors:  P A Wolf; T R Dawber; H E Thomas; W B Kannel
Journal:  Neurology       Date:  1978-10       Impact factor: 9.910

6.  Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates.

Authors:  W B Kannel; P A Wolf; E J Benjamin; D Levy
Journal:  Am J Cardiol       Date:  1998-10-16       Impact factor: 2.778

7.  Occurrence of death and stroke in patients in 47 countries 1 year after presenting with atrial fibrillation: a cohort study.

Authors:  Jeff S Healey; Jonas Oldgren; Michael Ezekowitz; Jun Zhu; Prem Pais; Jia Wang; Patrick Commerford; Petr Jansky; Alvaro Avezum; Alben Sigamani; Albertino Damasceno; Paul Reilly; Alex Grinvalds; Juliet Nakamya; Akinyemi Aje; Wael Almahmeed; Andrew Moriarty; Lars Wallentin; Salim Yusuf; Stuart J Connolly
Journal:  Lancet       Date:  2016-08-08       Impact factor: 79.321

8.  Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013.

Authors: 
Journal:  Lancet       Date:  2014-12-18       Impact factor: 79.321

9.  External review and validation of the Swedish national inpatient register.

Authors:  Jonas F Ludvigsson; Eva Andersson; Anders Ekbom; Maria Feychting; Jeong-Lim Kim; Christina Reuterwall; Mona Heurgren; Petra Otterblad Olausson
Journal:  BMC Public Health       Date:  2011-06-09       Impact factor: 3.295

10.  The Stockholm CREAtinine Measurements (SCREAM) project: protocol overview and regional representativeness.

Authors:  Björn Runesson; Alessandro Gasparini; Abdul Rashid Qureshi; Olof Norin; Marie Evans; Peter Barany; Björn Wettermark; Carl Gustaf Elinder; Juan Jesús Carrero
Journal:  Clin Kidney J       Date:  2015-11-14
View more
  11 in total

Review 1.  Tryptophan-Derived Uremic Toxins and Thrombosis in Chronic Kidney Disease.

Authors:  Tawfik Addi; Laetitia Dou; Stéphane Burtey
Journal:  Toxins (Basel)       Date:  2018-10-12       Impact factor: 4.546

2.  Moderate chronic kidney disease and left atrial enlargement independently predict thromboembolic events and mortality in elderly patients with atrial fibrillation: a retrospective single-center study.

Authors:  Hai-Jun Wang; Kai-Liang Li; Jian Li; Kun Lin; Yang Shi; Hao Wang; Quan-Jin Si; Yu-Tang Wang
Journal:  J Int Med Res       Date:  2019-07-21       Impact factor: 1.671

3.  Cellular and molecular mechanisms associated with ischemic stroke severity in female mice with chronic kidney disease.

Authors:  Lucie Hénaut; Maria Grissi; François Brazier; Maryam Assem; Sabrina Poirot-Leclercq; Gaëlle Lenglet; Cédric Boudot; Carine Avondo; Agnès Boullier; Gabriel Choukroun; Ziad A Massy; Saïd Kamel; Jean-Marc Chillon
Journal:  Sci Rep       Date:  2019-04-23       Impact factor: 4.379

4.  Atrial Fibrillation and Longitudinal Change in Cognitive Function in CKD.

Authors:  Mark D McCauley; Jesse Y Hsu; Ana C Ricardo; Dawood Darbar; Mayank Kansal; Manjula Kurella Tamura; Harold I Feldman; John W Kusek; Jonathan J Taliercio; Panduranga S Rao; Tariq Shafi; Jiang He; Xue Wang; Daohang Sha; Melissa Lamar; Alan S Go; Kristine Yaffe; James P Lash
Journal:  Kidney Int Rep       Date:  2021-01-05

5.  Validation of risk scores for ischaemic stroke in atrial fibrillation across the spectrum of kidney function.

Authors:  Ype de Jong; Edouard L Fu; Merel van Diepen; Marco Trevisan; Karolina Szummer; Friedo W Dekker; Juan J Carrero; Gurbey Ocak
Journal:  Eur Heart J       Date:  2021-04-14       Impact factor: 29.983

Review 6.  Optimizing indices of atrial fibrillation susceptibility and burden to evaluate atrial fibrillation severity, risk and outcomes.

Authors:  Giuseppe Boriani; Marco Vitolo; Igor Diemberger; Marco Proietti; Anna Chiara Valenti; Vincenzo Livio Malavasi; Gregory Y H Lip
Journal:  Cardiovasc Res       Date:  2021-06-16       Impact factor: 13.081

7.  Risk prediction of clinical adverse outcomes with machine learning in a cohort of critically ill patients with atrial fibrillation.

Authors:  Lorenzo Falsetti; Matteo Rucco; Marco Proietti; Giovanna Viticchi; Vincenzo Zaccone; Mattia Scarponi; Laura Giovenali; Gianluca Moroncini; Cinzia Nitti; Aldo Salvi
Journal:  Sci Rep       Date:  2021-09-23       Impact factor: 4.379

8.  Chronic kidney disease and atrial fibrillation: A dangerous combination.

Authors:  Gurbey Ocak; Meriem Khairoun; Othman Khairoun; Willem Jan W Bos; Edouard L Fu; Maarten J Cramer; Jan Westerink; Marianne C Verhaar; Frank L Visseren
Journal:  PLoS One       Date:  2022-04-07       Impact factor: 3.240

9.  Interatrial block, P terminal force or fragmented QRS do not predict new-onset atrial fibrillation in patients with severe chronic kidney disease.

Authors:  Tapio Hellman; Markus Hakamäki; Roosa Lankinen; Niina Koivuviita; Jussi Pärkkä; Petri Kallio; Tuomas Kiviniemi; K E Juhani Airaksinen; Mikko J Järvisalo; Kaj Metsärinne
Journal:  BMC Cardiovasc Disord       Date:  2020-10-07       Impact factor: 2.298

10.  Associations of blood biomarkers with glomerular filtration rate in patients with TIA and stroke: population-based study.

Authors:  Dearbhla M Kelly; Linxin Li; Annette I Burgess; Deborah L Poole; Julia M Duerden; Peter M Rothwell
Journal:  Stroke Vasc Neurol       Date:  2020-09-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.